Brokerages Anticipate Gemphire Therapeutics Inc (GEMP) Will Post Earnings of -$0.50 Per Share

Brokerages expect Gemphire Therapeutics Inc (NASDAQ:GEMP) to report earnings per share (EPS) of ($0.50) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Gemphire Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.41). Gemphire Therapeutics reported earnings of ($0.82) per share in the same quarter last year, which would indicate a positive year over year growth rate of 39%. The company is expected to issue its next quarterly earnings report on Monday, November 12th.

According to Zacks, analysts expect that Gemphire Therapeutics will report full year earnings of ($1.99) per share for the current fiscal year, with EPS estimates ranging from ($2.23) to ($1.86). For the next year, analysts forecast that the business will report earnings of ($2.13) per share, with EPS estimates ranging from ($2.50) to ($1.59). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Gemphire Therapeutics.

Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings results on Monday, August 13th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.05.

GEMP has been the topic of several analyst reports. Roth Capital lifted their price target on shares of Gemphire Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 27th. Canaccord Genuity reaffirmed a “buy” rating and set a $6.00 price target on shares of Gemphire Therapeutics in a research report on Monday, August 13th. Zacks Investment Research raised shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research report on Tuesday, August 14th. Jefferies Financial Group lowered shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating and set a $15.00 price target on the stock. in a research report on Monday, August 13th. Finally, ValuEngine upgraded shares of Gemphire Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 5th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Gemphire Therapeutics has a consensus rating of “Hold” and an average target price of $17.82.

A number of institutional investors have recently bought and sold shares of GEMP. Millennium Management LLC acquired a new stake in Gemphire Therapeutics in the 2nd quarter valued at approximately $1,981,000. Highland Capital Management LP acquired a new stake in Gemphire Therapeutics in the 1st quarter valued at approximately $700,000. DAFNA Capital Management LLC acquired a new stake in Gemphire Therapeutics in the 1st quarter valued at approximately $651,000. Nomura Holdings Inc. acquired a new stake in Gemphire Therapeutics in the 2nd quarter valued at approximately $556,000. Finally, Acadian Asset Management LLC acquired a new stake in Gemphire Therapeutics in the 2nd quarter valued at approximately $286,000. Hedge funds and other institutional investors own 32.60% of the company’s stock.

Shares of GEMP stock traded down $0.01 during trading on Wednesday, hitting $2.22. 185,000 shares of the stock traded hands, compared to its average volume of 498,092. The firm has a market cap of $32.67 million, a PE ratio of -0.69 and a beta of 1.35. The company has a debt-to-equity ratio of 0.50, a quick ratio of 4.64 and a current ratio of 4.64. Gemphire Therapeutics has a 52-week low of $0.83 and a 52-week high of $11.43.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.

Recommended Story: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply